-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
RVMD:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 38.42Change
-0.41 (-1.06)%Market Cap
USD 6.22BVolume
0.81MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 38.42Change
-0.41 (-1.06)%Market Cap
USD 6.22BVolume
0.81MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
N/A |
USD 122.24B |
REGN | Regeneron Pharmaceuticals Inc |
N/A |
USD 115.08B |
MRNA | Moderna Inc |
N/A |
USD 51.07B |
ALNY | Alnylam Pharmaceuticals Inc |
N/A |
USD 28.20B |
ARGX | argenx NV ADR |
N/A |
USD 26.78B |
BNTX | BioNTech SE |
N/A |
USD 20.40B |
BGNE | BeiGene Ltd |
N/A |
USD 17.50B |
GMAB | Genmab AS |
N/A |
USD 16.65B |
BMRN | Biomarin Pharmaceutical Inc |
N/A |
USD 15.98B |
RPRX | Royalty Pharma Plc |
N/A |
USD 15.90B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
XDNA:CA | iShares Genomics Immunolo.. | 5.59 % | 0.00 % |
N/A |
CAD 4.90M |
CURE:AU | ETFS S&P Biotech ETF | 1.30 % | 0.00 % |
N/A |
USD 0.04B |
XBI | SPDR® S&P Biotech ETF | 1.30 % | 0.35 % |
N/A |
USD 6.65B |
CNCR | Loncar Cancer Immunothera.. | 0.00 % | 0.79 % |
N/A |
USD 0.02B |
LABU | Direxion Daily S&P Biotec.. | 0.00 % | 1.14 % |
N/A |
USD 1.01B |
IDNA | iShares Genomics Immunolo.. | 0.00 % | 0.00 % |
N/A |
USD 0.14B |
SBIO | ALPS Medical Breakthrough.. | 0.00 % | 0.50 % |
N/A |
USD 0.11B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 33.96% | 83% | B | 89% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 33.96% | 83% | B | 89% | A- | ||
Trailing 12 Months | |||||||
Capital Gain | 43.57% | 84% | B | 89% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 43.57% | 84% | B | 88% | B+ | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 3.66% | 62% | D | 56% | F | ||
Dividend Return | 3.66% | 62% | D | 52% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 35.31% | 76% | C+ | 52% | F | ||
Risk Adjusted Return | 10.37% | 68% | D+ | 48% | F | ||
Market Capitalization | 6.22B | 96% | N/A | 90% | A- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector